Smarter drug design with molecular glues

Join Pharmaron and leading drug discovery experts for an in-depth look at the rapidly evolving field of molecular glues. This insightful on-demand mini-series will cover the origins, mechanisms, and therapeutic potential of molecular glue degraders, featuring real-world case studies that showcase innovative strategies for hit identification and characterization.

Part 1

What does Part 1 cover?

• An introduction to molecular glues
• Case study no.1: Hit identification was carried out using biophysical methods to discover a stabilizer of the SLP76/14-3-3 protein–protein interaction (PPI).
• Case study no.2: This work focuses on the rational design of novel molecular glue degraders that target BRD9 by recruiting the E3 ligase adaptor DCAF16.

About the speakers

• Marta Carrara - Associate Director of Target Validation at Amphista Therapeutics
• Marta Westwood - Director/Senior Principal Scientist, Biophysics at Pharmaron
• Amy Brown - Biologist, Drug Discovery Services at Pharmaron
• Moderated by Chris Wellaway - Associate Director, Medicinal Chemistry, Drug Discovery at Pharmaron

Part 1 is ready to view right now. Sign up to watch it on demand.

Part 2

Molecular Glues: Case Studies and Future Perspectives

What does Part 2 cover?

• The discovery of CK1α
• Key insights into novel hit finding assays for molecular glues
• Emerging technologies and future perspectives

About the speakers

• Marta Carrara - Associate Director of Target Validation at Amphista Therapeutics
• Marta Westwood - Director/Senior Principal Scientist, Biophysics at Pharmaron
• Amy Brown - Biologist, Drug Discovery Services at Pharmaron
• Moderated By Chris Wellaway - Associate Director, Medicinal Chemistry, Drug Discovery at Pharmaron